Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Fine-Tuning of Sox17 and Canonical Wnt Coordinates the Permeability Properties of the Blood-Brain Barrier.

Corada M, Orsenigo F, Bhat GP, Conze LL, Breviario F, Cunha SI, Claesson-Welsh L, Beznoussenko GV, Mironov AA, Bacigaluppi M, Martino G, Pitulescu ME, Adams RH, Magnusson P, Dejana E.

Circ Res. 2019 Feb 15;124(4):511-525. doi: 10.1161/CIRCRESAHA.118.313316.

2.
3.

VE-Cadherin-Mediated Epigenetic Regulation of Endothelial Gene Expression.

Morini MF, Giampietro C, Corada M, Pisati F, Lavarone E, Cunha SI, Conze LL, O'Reilly N, Joshi D, Kjaer S, George R, Nye E, Ma A, Jin J, Mitter R, Lupia M, Cavallaro U, Pasini D, Calado DP, Dejana E, Taddei A.

Circ Res. 2018 Jan 19;122(2):231-245. doi: 10.1161/CIRCRESAHA.117.312392. Epub 2017 Dec 12.

4.

Deregulated TGF-β/BMP Signaling in Vascular Malformations.

Cunha SI, Magnusson PU, Dejana E, Lampugnani MG.

Circ Res. 2017 Sep 29;121(8):981-999. doi: 10.1161/CIRCRESAHA.117.309930. Review.

PMID:
28963191
5.

Compound genetically engineered mouse models of cancer reveal dual targeting of ALK1 and endoglin as a synergistic opportunity to impinge on angiogenic TGF-β signaling.

Eleftheriou NM, Sjölund J, Bocci M, Cortez E, Lee SJ, Cunha SI, Pietras K.

Oncotarget. 2016 Dec 20;7(51):84314-84325. doi: 10.18632/oncotarget.12604.

6.

Functional Characterization of Germline Mutations in PDGFB and PDGFRB in Primary Familial Brain Calcification.

Vanlandewijck M, Lebouvier T, Andaloussi Mäe M, Nahar K, Hornemann S, Kenkel D, Cunha SI, Lennartsson J, Boss A, Heldin CH, Keller A, Betsholtz C.

PLoS One. 2015 Nov 23;10(11):e0143407. doi: 10.1371/journal.pone.0143407. eCollection 2015.

7.

Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer.

Cunha SI, Bocci M, Lövrot J, Eleftheriou N, Roswall P, Cordero E, Lindström L, Bartoschek M, Haller BK, Pearsall RS, Mulivor AW, Kumar R, Larsson C, Bergh J, Pietras K.

Cancer Res. 2015 Jun 15;75(12):2445-56. doi: 10.1158/0008-5472.CAN-14-3706. Erratum in: Cancer Res. 2016 Oct 15;76(20):6131-6132.

8.

Bone morphogenetic protein-9 inhibits lymphatic vessel formation via activin receptor-like kinase 1 during development and cancer progression.

Yoshimatsu Y, Lee YG, Akatsu Y, Taguchi L, Suzuki HI, Cunha SI, Maruyama K, Suzuki Y, Yamazaki T, Katsura A, Oh SP, Zimmers TA, Lee SJ, Pietras K, Koh GY, Miyazono K, Watabe T.

Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):18940-5. doi: 10.1073/pnas.1310479110. Epub 2013 Oct 16.

9.

Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination.

Anderberg C, Cunha SI, Zhai Z, Cortez E, Pardali E, Johnson JR, Franco M, Páez-Ribes M, Cordiner R, Fuxe J, Johansson BR, Goumans MJ, Casanovas O, ten Dijke P, Arthur HM, Pietras K.

J Exp Med. 2013 Mar 11;210(3):563-79. doi: 10.1084/jem.20120662. Epub 2013 Feb 11.

10.

ALK1 as an emerging target for antiangiogenic therapy of cancer.

Cunha SI, Pietras K.

Blood. 2011 Jun 30;117(26):6999-7006. doi: 10.1182/blood-2011-01-330142. Epub 2011 Apr 5. Review.

11.

Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis.

Cunha SI, Pardali E, Thorikay M, Anderberg C, Hawinkels L, Goumans MJ, Seehra J, Heldin CH, ten Dijke P, Pietras K.

J Exp Med. 2010 Jan 18;207(1):85-100. doi: 10.1084/jem.20091309. Epub 2010 Jan 11.

Supplemental Content

Loading ...
Support Center